© 2001 European Society of Cardiology
A cost-effectiveness analysis of bisoprolol for heart failure
Imperial College School of Medicine, NHLI-Royal Brompton Campus Dovehouse Street, SW3 6LY, UK
 |
Abstract |
|---|
Aims: This study considers the cost-effectiveness of bisoprolol in heart failure patients as an adjunctive therapy to usual treatment.
Methods and results: A cost-effectiveness model was constructed using data available from the CIBIS I & II trials and other secondary sources. Differences in patient survival rates were calculated for bisoprolol (n = 1327) and placebo groups (n = 1320) extrapolating data over a 5-year period, under limited and extended benefits scenarios to calculate life years gained (LYG). Hospitalisation rates were calculated using data from both CIBIS trials. Costs were considered under two different patient management protocols for treatment initiation — shared care by outpatient clinics and GPs and initiation by a nurse working in the community. Discounted LYG were calculated to be 0.228 under the limited benefits scenario and 0.368 under the extended benefits scenario. Under the extended benefits scenario shared care resulted in a cost of £268 per LYG or £412 per LYG for community initiation. Under the limited benefits scenario the costs were a £135 saving and £69, respectively.
Conclusion: This analysis has shown bisoprolol to be an economically attractive therapy in comparison with other treatments. It is hoped that its adoption by clinicians will be rapid, despite the labour intensive and time consuming up-titration process involved in its initiation.
Key Words: Cost-effective • Beta-blockers • Heart failure • Bisoprolol
Received August 14, 2000; Revised December 28, 2000; Accepted January 17, 2001
* Tel.: +44-20-7351-8700; fax: +44-20-7351-8733. E-mail address: s.varney{at}rbh.nthames.nhs.uk (S. Varney).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, and K Khunti Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care Heart, December 1, 2008; 94(12): 1601 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ledwidge, M. Barry, J. Cahill, E. Ryan, B. Maurer, M. Ryder, B. Travers, L. Timmons, and K. McDonald Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? Eur J Heart Fail, June 1, 2003; 5(3): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krum and S. Lim Pharmacoeconomics of beta-blockers: effective and cost-effective therapy in chronic heart failure Eur J Heart Fail, August 1, 2001; 3(4): 399 - 402. [Full Text] [PDF]
|
|